Author
|
Year
|
Country
|
Ethnicity
|
Cancer site
|
Case–control
|
Gendera
|
Soure of control
|
Genotyping method
|
HWE
|
---|
Ribeiro AL
|
2013
|
Portugal
|
Caucasian
|
Breast cancer
|
96/74
|
Female
|
HB
|
PCR-RFLP
|
0.00
|
Alves LR
|
2012
|
Brazil
|
Brazilian
|
Head and neck cancer
|
88/40
|
Mixed
|
PB
|
PCR-RFLP
|
0.69
|
Li P
|
2012
|
China
|
Asian
|
Prostate cancer
|
662/716
|
Male
|
PB
|
TaqMan
|
0.55
|
Mera-Menendez F
|
2012
|
Spain
|
Caucasian
|
Head and neck cancer
|
121/154
|
Mixed
|
PB
|
PCR–RFLP
|
0.69
|
Ruiz-Tovar J
|
2012
|
Spain
|
Caucasian
|
Pancreatic cancer
|
59/159
|
Mixed
|
PB
|
PCR-RFLP
|
0.68
|
Kuo WH
|
2012
|
China
|
Asian
|
Lung cancer
|
285/300
|
Mixed
|
PB
|
PCR–RFLP
|
0.15
|
Qin C
|
2012
|
China
|
Asian
|
Renal cell carcinoma
|
620/623
|
Mixed
|
PB
|
PCR-RFLP
|
0.42
|
Wang X
|
2011
|
China
|
Asian
|
Pancreatic cancer
|
263/271
|
Mixed
|
PB
|
PCR-RFLP
|
0.49
|
Putra AC
|
2011
|
Japan
|
Asian
|
Lung cancer
|
83/110
|
Mixed
|
PB
|
PCR
|
0.65
|
Kim YH
|
2011
|
Korea
|
Asian
|
Other cancer
|
199/215
|
Female
|
PB
|
PCR-RFLP
|
0.14
|
Shieh TM
|
2010
|
China
|
Asian
|
Head and neck cancer
|
305/96
|
Mixed
|
PB
|
PCR-RFLP
|
0.71
|
Hsiao PC
|
2010
|
China
|
Asian
|
Other cancer
|
102/347
|
Mixed
|
HB
|
PCR-RFLP
|
0.70
|
Chen MK
|
2009
|
China
|
Asian
|
Head and neck cancer
|
174/347
|
Mixed
|
PB
|
PCR-RFLP
|
0.70
|
Naidu R
|
2009
|
Malaysia
|
Asian
|
Breast cancer
|
410/275
|
Female
|
PB
|
PCR-RFLP
|
0.90
|
Konac E
|
2009
|
Turkey
|
Caucasian
|
Lung cancer
|
141/156
|
Mixed
|
HB
|
PCR-RFLP
|
0.94
|
Li K
|
2009
|
China
|
Asian
|
Other cancer
|
87/106
|
Mixed
|
PB
|
PCR
|
0.76
|
Munoz-Guerra MF
|
2009
|
Spain
|
Caucasian
|
Head and neck cancer
|
74/139
|
Mixed
|
PB
|
PCR-RFLP
|
0.69
|
Kim HO
|
2008
|
Korea
|
Asian
|
Breast cancer
|
90/102
|
Female
|
PB
|
PCR
|
0.06
|
Apaydin I
|
2008
|
Turkey
|
Caucasian
|
Breast cancer
|
102/102
|
Female
|
PB
|
PCR-RFLP
|
0.84
|
Li H
|
2007
|
USA
|
Mixed
|
Prostate cancer
|
1072/1271
|
Male
|
PB
|
PCR-RFLP
|
0.81
|
Orr-Urtreger A
|
2007
|
Israel
|
Caucasian
|
Prostate cancer
|
402/300
|
Male
|
PB
|
PCR-RFLP
|
0.95
|
Fransen K
|
2006
|
Sweden
|
Caucasian
|
Other cancer
|
198/258
|
Mixed
|
PB
|
PCR-RFLP
|
0.77
|
Konac E-O
b
|
2007
|
Turkey
|
Caucasian
|
Other cancer
|
49/107
|
Female
|
PB
|
PCR-RFLP
|
0.00
|
Konac E-C
c
|
2007
|
Turkey
|
Caucasian
|
Other cancer
|
32/107
|
Female
|
PB
|
PCR-RFLP
|
0.00
|
Konac E-E
d
|
2007
|
Turkey
|
Caucasian
|
Other cancer
|
21/107
|
Female
|
PB
|
PCR-RFLP
|
0.00
|
Ollerenshaw M
|
2004
|
UK
|
Caucasian
|
Renal cell carcinoma
|
160/288
|
Mixed
|
PB
|
PCR-RFLP
|
0.00
|
Tanimoto K
|
2003
|
Japan
|
Asian
|
Head and neck cancer
|
55/110
|
Mixed
|
PB
|
PCR-RFLP
|
0.65
|
Clifford SC
|
2001
|
UK
|
Caucasian
|
Renal cell carcinoma
|
35/143
|
Mixed
|
HB
|
PCR-RFLP
|
0.00
|
- aMixed means samples contain both female and male; PB, public based; HB, hospital based; HWE, Hardy-Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; TaqMan, TaqMan SNP Genotyping Assays.
- bcdThe article of Konac E provided data on three kinds of cancers (cervical cancer, endometrial cancer and ovarian cancer), Konac E-O stands for ovarian cancer; Konac E-C stands for cervical cancer; Konac E-E stands for endometrial cancer.